Latest News and Press Releases

Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3...

Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...

Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...

PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...

CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global central nervous system disorders therapeutics market is estimated to be valued at US$ 131.3 million in...

- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...

Pune, India, March 22, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to reach USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast...

PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...